01:41:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Targovax är ett norskt läkemedelsbolag som utvecklar riktad immunterapi vid behandling hos cancerpatienter. Bolagets verksamhet består av en stor del forskning och utveckling inom området och produkterna säljs under separata varumärken. Även partnerskap ingås för att stärka samarbetet inom utvecklingen av immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Oslo.

Kalender

2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 Ordinarie utdelning TRVX 0.00 NOK
2019-04-09 Årsstämma 2018
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 Ordinarie utdelning TRVX 0.00 NOK
2018-04-11 Årsstämma 2017
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma 2016
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 Ordinarie utdelning TRVX 0.00 NOK
2016-04-13 Årsstämma 2015
2015-06-23 Ordinarie utdelning TRVX 0.00 NOK
2015-06-22 Årsstämma 2014
2019-06-12 08:38:29

Oslo, 12 June 2019: The board of directors of Targovax ASA (the "Company") has resolved to increase the share capital of the Company following the completion of a settlement period for vested restricted stock units ("RSUs"). The settlement period commenced on 29 May 2019 at 10:00 hours (CET) and ended on 11 June 2019 at 10:00 hours (CET).

1. Settlement of RSUs

In total were 102,735 RSUs settled, giving the board members settling vested RSUs the right to subscribe for in total 102,735 shares, each with a par value of NOK 0.10.

Reference is made to the mandatory notifications of trade made by the following primary insiders:

- On 31 May 2019, board member Bente-Lill Bjerkelund Romøren notified that she had settled 5,464 RSUs;

- On 6 June 2019, board member Diane Mellett notified that she had settled 17,704 RSUs; and

- On 6 June 2019, board member Eva-Lotta Allan notified that she had settled 51,368 RSUs.

In addition has board member Robert Burns (the "Primary Insider") settled 28,199 RSUs giving him the right to subscribe for an equal number of shares in the Company at a subscription price of NOK 0.10 per share. The Primary Insider has transferred his right to the shares to a third party to sell the corresponding amount of shares in the market in order to cover the Primary Insider's tax cash impact from the RSU settlement. Further information regarding the shares sold by the third party to cover the tax impact of the Primary Insider and the Primary Insiders total holding of shares following the settlement will be published in a separate stock exchange notice as soon as the details are final.

2. Resolutions to increase the share capital in Targovax ASA 

The Company's board of directors has, in accordance with the authorisations granted by the general meeting on 30 April 2019, resolved to increase the Company's share capital with NOK 10,273.50 by issuance of 102,735 new shares, each with a nominal value of NOK 0.10 in order to facilitate the settlement of RSUs.

The new share capital in the Company will accordingly be NOK 6,338,361.30 divided into 63 383 613 shares, each with a nominal value of NOK 0.10. The share capital increase will be registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret) as soon as practically possible.

For further information, please contact:

Torbjørn Furuseth, CFO
Phone: + 47 932 11 101
Email: torbjorn.furuseth@targovax.com